Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 3,100,000 | $317.75M |
| Grant or award | 12 | 265,180 | |
| Option exercise | 2 | 2,000 | |
| Bona-fide gift | 4 | 53,102 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
35 Form 4 filings on record, the earliest from Oct 25, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Lance G. Laing - Officer | Grant or award | Common Stock | 20,000 | $0.00 | - | |
| Lance G. Laing - Officer | Grant or award | Performance Stock Units | 10,000 | $0.00 | - | |
| Brian F. Sullivan - Officer | Grant or award | Common Stock | 80,000 | $0.00 | - | |
| Brian F. Sullivan - Officer | Grant or award | Performance Stock Units | 120,000 | $0.00 | - | |
| Vicky Hahne - Officer | Grant or award | Common Stock | 16,000 | $0.00 | - | |
| Vicky Hahne - Officer | Grant or award | Performance Stock Units | 10,000 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Open-market sale | Common Stock | 261,368 | $102.50 | $26.79M | |
| BAKER BROS. ADVISORS LP | Open-market sale | Common Stock | 2,838,632 | $102.50 | $290.96M | |
| Gift | Stock Option (right to buy) | 14,048 | $0.00 | - | ||
| Gift | Stock Option (right to buy) | 14,048 | $0.00 | - | ||
| Richard E. Buller | Gift | Stock Option (right to buy) | 12,503 | $0.00 | - | |
| Richard E. Buller | Gift | Stock Option (right to buy) | 12,503 | $0.00 | - | |
| Grant or award | Common Stock | 1,530 | $0.00 | - | ||
| Grant or award | Common Stock | 1,530 | $0.00 | - | ||
| Charles R. Romp | Grant or award | Common Stock | 1,530 | $0.00 | - | |
| Richard Nigon | Grant or award | Common Stock | 1,530 | $0.00 | - | |
| Leo Furcht | Grant or award | Common Stock | 1,530 | $0.00 | - | |
| Richard E. Buller | Grant or award | Common Stock | 1,530 | $0.00 | - | |
| Lance G. Laing - Officer | Option exercise | Common Stock | 1,000 | $9.89 | $10K | |
| Lance G. Laing - Officer | Option exercise | Stock Option (right to buy) | 1,000 | $0.00 | - | |
| Richard E. Buller | Gift | Common Stock | 1,029 | $0.00 | - | |
| Richard E. Buller | Gift | Common Stock | 1,029 | $0.00 | - | |
| Open-market sale | Common Stock | 25,000 | $140.68 | $3.52M | ||
| Richard E. Buller | Option exercise | Common Stock | 9,000 | $5.10 | $46K | |
| Richard E. Buller | Open-market sale | Common Stock | 1,289 | $137.00 | $177K | |
| Richard E. Buller | Open-market sale | Common Stock | 550 | $139.00 | $76K | |
| Richard E. Buller | Open-market sale | Common Stock | 1,670 | $139.58 | $233K | |
| Richard E. Buller | Open-market sale | Common Stock | 2,301 | $141.03 | $325K | |
| Richard E. Buller | Open-market sale | Common Stock | 2,825 | $142.04 | $401K | |
| Richard E. Buller | Open-market sale | Common Stock | 365 | $143.24 | $52K | |
| Richard E. Buller | Option exercise | Stock Option (right to buy) | 9,000 | $0.00 | - | |
| Richard Nigon | Gift | Common Stock | 10,000 | $0.00 | - | |
| Richard E. Buller | Option exercise | Common Stock | 3,000 | $5.10 | $15K | |
| Richard E. Buller | Open-market sale | Common Stock | 2,325 | $110.11 | $256K | |
| Richard E. Buller | Open-market sale | Common Stock | 675 | $110.83 | $75K | |
| Richard E. Buller | Option exercise | Stock Option (right to buy) | 3,000 | $0.00 | - | |
| Charles R. Romp | Grant or award | Common Stock | 215 | $0.00 | - | |
| Open-market sale | Common Stock | 20,000 | $120.03 | $2.40M | ||
| Richard Nigon | Gift | Common Stock | 19,975 | $0.00 | - | |
| Richard E. Buller | Option exercise | Common Stock | 1,100 | $14.83 | $16K | |
| Richard E. Buller | Open-market sale | Common Stock | 1,100 | $98.13 | $108K | |
| Richard E. Buller | Gift | Common Stock | 500 | $0.00 | - | |
| Richard E. Buller | Option exercise | Stock Option (right to buy) | 1,100 | $0.00 | - | |
| Open-market sale | Common Stock | 15,000 | $100.00 | $1.50M | ||
| Richard E. Buller | Option exercise | Common Stock | 3,900 | $14.83 | $58K | |
| Richard E. Buller | Open-market sale | Common Stock | 3,900 | $96.73 | $377K | |
| Richard E. Buller | Option exercise | Stock Option (right to buy) | 3,900 | $0.00 | - | |
| Richard E. Buller | Gift | Common Stock | 500 | $0.00 | - | |
| Richard Nigon | Other | Common Stock | 4,672 | $7.56 | $35K | |
| Richard Nigon | Other | Common Stock | 3,245 | $7.56 | $25K | |
| Richard Nigon | Other | Warrants (right to buy) | 4,672 | $0.00 | - | |
| Richard Nigon | Other | Warrants (right to buy) | 3,245 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 13,976 | $56.22 | $786K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 151,524 | $56.22 | $8.52M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 388 | $58.02 | $23K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 4,212 | $58.02 | $244K | |
| Brian F. Sullivan - Officer | Other | Common Stock | 104,340 | $8.05 | $840K | |
| Brian F. Sullivan - Officer | Other | Warrants (right to buy) | 104,340 | $0.00 | - | |
| Vicky Hahne - Officer | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
| Lance G. Laing - Officer | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| Brian F. Sullivan - Officer | Grant or award | Stock Option (right to buy) | 250,000 | $0.00 | - | |
| Brian F. Sullivan - Officer | Grant or award | Stock Option (right to buy) | 150,000 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Celcuity Inc. (CELC) had 13 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for CELC runs to 35 Form 4 filings, the earliest from 2024-10-25. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CELC were filed in the last 90 days. 4 purchases are on record for this company.
2 insider sales of CELC were filed in the last 90 days, totaling $317.75M.
This page tracks CELC Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CELC to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.